Eyepoint Pharmaceuticals, Inc.
Clinical trials sponsored by Eyepoint Pharmaceuticals, Inc., explained in plain language.
-
New eye drug could cut injection burden for wet AMD patients
Disease control OngoingThis phase 3 study tests a new drug, EYP-1901, against a standard treatment (aflibercept) for wet age-related macular degeneration, a leading cause of vision loss. About 400 adults with the condition will receive either EYP-1901 or aflibercept to see if the new drug can maintain …
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 10:49 UTC
-
New eye drug could mean fewer shots for wet AMD patients
Disease control OngoingThis phase 3 study tests EYP-1901, a new long-acting eye injection, against the standard treatment aflibercept in 400 people with wet age-related macular degeneration (AMD). The goal is to see if EYP-1901 can maintain or improve vision while reducing the number of injections need…
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 10:33 UTC